Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of ...

Reports

2

Domains carrying it

2

First reported

24 August 2026

Latest report

31 August 2026

◆ Sectors

◆ Where

Europe

◆ Timeline

1. 24 August 2026Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of ...biospace.com
2. 31 August 2026Arrowhead to Request FDA Priority Review for Plozasiran in Severe Hypertriglyceridemiaprecisionmedicineonline.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• Phanes Therapeutics Receives FDA Fast Track Designation for Spevatamig in Advanced ...2 reports · 2 domains · 17 August 2026
• Scholar Rock: FDA Grants Fast Track And Orphan Drug Designations To Apitegromab2 reports · 2 domains · 3 September 2026
• Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis4 reports · 4 domains · 4 September 2026
• How Investors Are Reacting To Replimune Group (REPL) FDA Accelerated Approval For ...4 reports · 4 domains · 10 August 2026
• Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold6 reports · 6 domains · 24 August 2026
• FDA sNDA Submission Is Planned for Selinexor Plus Ruxolitinib in Myelofibrosis2 reports · 2 domains · 1 August 2026

◆ Share

◆ Evidence

2 reports · 2 domains

• Arrowhead to Request FDA Priority Review for Plozasiran in Severe Hypertriglyceridemiaprecisionmedicineonline.com · 31 August 2026
• Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of ...biospace.com · 24 August 2026